Literature DB >> 25004497

Using routinely collected clinical assessments in mental health services: the resident assessment instrument-mental health.

Chris Perlman1, Lynn Martin2, John Hirdes1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25004497      PMCID: PMC4086312          DOI: 10.1177/070674371405900708

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


× No keyword cloud information.
Dear Editor: Dr Urbanoski and colleagues1 examined the use of the Resident Assessment Instrument–Mental Health (RAI-MH) for specialized inpatient mental health services. While the article underscores the importance of a comprehensive approach to implementation (for example, training or information technology infrastructure), much of the critique appears to reflect a lack of understanding of the design and applications of the RAI-MH. Urbanoski et al imply that the RAI-MH system was developed outside of real-world contexts when, in fact, front-line clinicians were engaged in all aspects of the development and refinement of the instrument and its applications. Numerous studies since the development work were based on data collected within routine clinical practice, including research on the Cognitive Performance Scale,2 Clinical Assessment Protocols,3,4 and quality indicators.5 The suggestion that most RAI-MH scales are “irrelevant for most patients”1, p 692 is particularly surprising and misguided. The authors incorrectly identified several scales as outcome measures, or had flawed operationalizations of specific scales. For example, the embedded CAGE (Cut down, Annoyed, Guilty, and Eye-opener) index was evaluated as an outcome measure when it was intended only to be used as a screener for substance abuse. The authors failed to consider the 90-day, look-back period for the RAI-MH items used to populate the CAGE (that is, there may have been overlap between time 1 and 2 observations). Further, conclusions that the RAI-MH lacks indicators of addiction severity are misleading, given that it includes numerous items related to substance and alcohol use, gambling, mental state, involvement with the criminal justice system, and vocational and interpersonal functioning. These measures provide ample opportunity to derive meaningful indices of addiction severity. Urbanoski et al1 also appear to have incorrectly calculated scale values in their study, which makes their conclusions about the use of these scales among specialized populations questionable. A range of 0 to 8 was reported for the Positive Symptom Scale (PSS), though this scale should range from 0 to 12. We analyzed RAI-MH data provided by the Canadian Institute for Health Information for 276 055 people with and without schizophrenia in 75 hospitals across Ontario between 2005 and 2012. The mean PSS was 1.20 (SD 2.22) for people without schizophrenia, and 4.15 (SD 3.25) among people with schizophrenia or other psychotic disorders. For people with schizophrenia, an effect size of 1.32 was found for change in the PSS between admission and discharge assessments. These findings provide clear evidence in support of the PSS. Urbanoski et al1 conclude that the difficulties experienced by a single organization’s implementation of an assessment system cannot be attributed to “either to the assessment platform or to issues of staff motivation and compliance.”1, p 693 Real-world evidence from 74 other hospitals would appear to contradict Urbanoski et al’s report. It is concerning that staff interviewed in this study identified little value in an assessment that includes items paramount to mental health care, including harm to self and others, social and vocational functioning, and traumatic life events, among others previously mentioned. Perhaps the implementation of innovative decision support applications for the RAI-MH in shared clinical decision-making contexts may enhance applications of this system. Dear Editor: We appreciate the attention that Dr Perlman et al1 have brought to our work2 with their letter, and are happy to take this opportunity to both clarify some of our original interpretations and to respectfully disagree on certain points they raise. First, we did not intend to imply that the Resident Assessment Instrument–Mental Health (RAI-MH) system was developed outside of clinical contexts. We used the phrase real-world to describe our own focus on the implementation and clinical use of the system at one facility, not to contrast it favourably with the work done by the developers. Second, Dr Perlman et al1 challenge our argument that most RAI-MH scales are irrelevant for most patients. While the suite of scales captures the psychopathology of most patients, only a few of the scales will apply to a given patient. This, in turn, results in skewed distributions and very low mean scores on most of the scales when they are used to characterize the patient population. This property of measures based on symptom assessments, and the resulting difficulties in scaling patient-level improvements, has been echoed elsewhere.3 We take responsibility if we were not sufficiently clear on this point. Third, Perlman et al1 suggest that we incorrectly identified scales as outcomes, giving the CAGE-AID (Cut down, Annoyed, Guilty, and Eye-opener–Questions Adapted to Include Drug use) as an example. We did not evaluate the CAGE-AID as an outcome; see Tables 3 to 5 in the article for the list of scales that were evaluated as outcomes.2 The confusion perhaps arises because we refer to the CAGE-AID when noting the lack of addiction-focused outcomes.2, p 694 Similarly, we did not fail to note the 90-day window on this measure; however, the potential overlap of recall windows would scarcely explain why only 12% of all patients, and only 36% of patients with a chart diagnosis of a substance use disorder, screened positive on the CAGE-AID. Fourth, we stand by our argument that the RAI-MH system is not particularly well-suited to assessment or outcome monitoring in addictions service settings. The RAI-MH does capture information on the recency of substance use and selected domains of interest (listed in Perlman et al1); however, it does not capture, for example, volume of use, route of administration, motivation for treatment, or for changing substance use, problem substances, family history, substance use within the client’s social network, sexual health, or most of the myriad of illegal behaviours associated with substance use and addiction. Moreover, the RAI-MH does not allow for the nuanced gradations of problem severity available from instruments such as the Addiction Severity Index4 or the Global Assessment of Individual Needs.5 Also relevant is that there is a separate suite of tools for assessment and treatment planning, offering better coverage of the above issues, mandated for use across Ontario’s addiction treatment system.6 Fifth, Perlman et al1 note that we miscalculated the scores of the Positive Symptom Scale (PSS). From our review of archived documentation, it appears that the PSS was scored out of 8 in 2007, while a newer version is scored out of 12. The data used in our study corresponded to the early years of RAI-MH implementation, which may explain this discrepancy. At any rate, scale scores are calculated automatically by the electronic assessment platform, reducing the possibility of investigator error. We would like to close by acknowledging that findings generated from studies conducted in other settings, on other patient populations, at other points in time, and (or) using other methods could indeed differ from our findings. There is no reason to expect anything different. Our work was a case study of the implementation of a mental health assessment platform at a single, large institution. It is not surprising to us that the impressions and feedback of clinical staff obtained during the development of the RAI-MH would differ from those of clinical staff charged with coding the instrument 3 years following its provincial mandate. We maintain that these perspectives, used in conjunction with data audits and reviews, are useful in guiding the refinement of assessment procedures in continually evolving clinical settings. We continue to believe that the best course is to refrain from blaming the clinical staff or the instrument for poor performance, and to collate the evidence generated from evaluation and research of different kinds to optimize care planning and assessment procedures. We conducted our evaluation of the RAI-MH assessment system in this spirit.
  7 in total

1.  Screening cognitive performance with the Resident Assessment Instrument for Mental Health Cognitive Performance Scale.

Authors:  Kendra Jones; Christopher M Perlman; John P Hirdes; Tracey Scott
Journal:  Can J Psychiatry       Date:  2010-11       Impact factor: 4.356

2.  Real-world evaluation of the Resident Assessment Instrument-Mental Health assessment system.

Authors:  Karen A Urbanoski; Benoit H Mulsant; Peggie Willett; Sahar Ehtesham; Brian Rush
Journal:  Can J Psychiatry       Date:  2012-11       Impact factor: 4.356

3.  A care planning strategy for traumatic life events in community mental health and inpatient psychiatry based on the InterRAI assessment instruments.

Authors:  Krista Mathias; J P Hirdes; D Pittman
Journal:  Community Ment Health J       Date:  2010-05-07

4.  The promise of PROMIS(®) for addiction.

Authors:  Thomas F Hilton
Journal:  Drug Alcohol Depend       Date:  2011-12-15       Impact factor: 4.492

5.  Predicting inpatient aggression using the InterRAI risk of harm to others clinical assessment protocol: a tool for risk assessment and care planning.

Authors:  Eva Neufeld; Christopher M Perlman; John P Hirdes
Journal:  J Behav Health Serv Res       Date:  2012-10       Impact factor: 1.505

6.  The Fifth Edition of the Addiction Severity Index.

Authors:  A T McLellan; H Kushner; D Metzger; R Peters; I Smith; G Grissom; H Pettinati; M Argeriou
Journal:  J Subst Abuse Treat       Date:  1992

7.  Development of mental health quality indicators (MHQIs) for inpatient psychiatry based on the interRAI mental health assessment.

Authors:  Christopher M Perlman; John P Hirdes; Howard Barbaree; Brant E Fries; Ian McKillop; John N Morris; Terry Rabinowitz
Journal:  BMC Health Serv Res       Date:  2013-01-10       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.